PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies

The use of [18F]- and [68Ga]-labeled inhibitors of prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of prostate cancer is now widespread. We have proposed a reporting and data system called PSMA-RADS version 1.0, which is a framework for classifying PSMA-targe...

Full description

Saved in:
Bibliographic Details
Published in:European urology 2018-04, Vol.73 (4), p.485-487
Main Authors: Rowe, Steven P., Pienta, Kenneth J., Pomper, Martin G., Gorin, Michael A.
Format: Article
Language:English
Subjects:
Fluorine Radioisotopes - pharmacology
Gallium Radioisotopes - pharmacology
Humans
Male
Positron-Emission Tomography - methods
Prostate - diagnostic imaging
Prostate-Specific Antigen - antagonists & inhibitors
Prostatic Neoplasms - diagnosis
Radiopharmaceuticals - pharmacology
Research Design - standards
Sensitivity and Specificity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of [18F]- and [68Ga]-labeled inhibitors of prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of prostate cancer is now widespread. We have proposed a reporting and data system called PSMA-RADS version 1.0, which is a framework for classifying PSMA-targeted PET scans and individual findings into categories that reflect the likelihood of the presence of prostate cancer.
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2017.10.027